BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 7521833)

  • 1. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
    Coukell AJ; Markham A
    Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Fitton A; McTavish D
    Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Dunn CJ; Fitton A; Sorkin EM
    Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clodronate: a review of its use in breast cancer.
    Hurst M; Noble S
    Drugs Aging; 1999 Aug; 15(2):143-67. PubMed ID: 10495073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.
    Ghinoi V; Brandi ML
    Expert Opin Pharmacother; 2002 Nov; 3(11):1643-56. PubMed ID: 12437497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
    Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
    Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibandronate.
    Dooley M; Balfour JA
    Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
    Rizzoli R; Buchs B; Bonjour JP
    Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.